Y. Yeh

A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis

Kak‐Shan Shia, M. Hung, Wenchi Hsiao, 2015, Diabetes, obesity & metabolism.

Modulating the affinity and signaling bias of cannabinoid receptor 1 antagonists.

Jen‐Shin Song, Kun-Yi Hsin, Kak‐Shan Shia, 2022, Bioorganic chemistry.

Induction of fatty acid oxidation resists weight gain, ameliorates hepatic steatosis and reduces cardiometabolic risk factors

Kak‐Shan Shia, M. Hung, R S Vijayakumar, 2012, International Journal of Obesity.

A structure-function approach identifies L-PGDS as a mediator responsible for glucocorticoid-induced leptin expression in adipocytes.

Lih-Yuan Lin, Kun-Yi Hsin, A. Zimmer, 2019, Biochemical pharmacology.

Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.

Y. Chao, Jen‐Shin Song, T. Yeh, 2009, Journal of medicinal chemistry.